These innovative agents represent a significant progression in the management of type 2 diabetes. Retatrutide, a combined GLP-1 and GIP receptor agonist, demonstrates promising efficacy in lowering blood glucose https://tomasuaqp561034.ltfblog.com/37707782/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide